Free Trial

Applied Therapeutics (APLT) Competitors

Applied Therapeutics logo
$0.49 +0.00 (+0.16%)
As of 12:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

APLT vs. PVLA, ATXS, SLRN, ITOS, CMPX, ALMS, MNPR, GLUE, CDTX, and AARD

Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Palvella Therapeutics (PVLA), Astria Therapeutics (ATXS), Acelyrin (SLRN), iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Alumis (ALMS), Monopar Therapeutics (MNPR), Monte Rosa Therapeutics (GLUE), Cidara Therapeutics (CDTX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry.

Applied Therapeutics vs.

Palvella Therapeutics (NASDAQ:PVLA) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.

Palvella Therapeutics has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

Applied Therapeutics received 66 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 57.14% of users gave Applied Therapeutics an outperform vote.

CompanyUnderperformOutperform
Palvella TherapeuticsOutperform Votes
14
100.00%
Underperform Votes
No Votes
Applied TherapeuticsOutperform Votes
80
57.14%
Underperform Votes
60
42.86%

Palvella Therapeutics' return on equity of -80.93% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Palvella TherapeuticsN/A -80.93% -59.55%
Applied Therapeutics N/A -260.75%-76.04%

Palvella Therapeutics currently has a consensus target price of $44.43, suggesting a potential upside of 104.74%. Applied Therapeutics has a consensus target price of $6.10, suggesting a potential upside of 1,157.21%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palvella Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Applied Therapeutics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Palvella Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 8 mentions for Palvella Therapeutics and 6 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 1.09 beat Palvella Therapeutics' score of 0.76 indicating that Applied Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palvella Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Applied Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Palvella Therapeutics has higher revenue and earnings than Applied Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palvella Therapeutics$42.81M5.60-$24.54M-$12.10-1.79
Applied Therapeutics$455K150.97-$119.76M-$0.95-0.51

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Palvella Therapeutics and Applied Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLT vs. The Competition

MetricApplied TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$68.69M$6.24B$5.22B$8.47B
Dividend YieldN/A3.01%4.99%4.19%
P/E Ratio-0.308.6526.4919.71
Price / Sales150.97268.83398.79120.61
Price / CashN/A65.8538.3134.62
Price / Book-2.436.266.684.51
Net Income-$119.76M$143.73M$3.22B$247.94M
7 Day Performance17.77%-0.38%0.08%3.40%
1 Month Performance47.84%4.55%5.42%11.07%
1 Year Performance-88.97%-7.57%13.21%5.78%

Applied Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLT
Applied Therapeutics
4.0236 of 5 stars
$0.49
+0.2%
$6.10
+1,155.1%
-89.5%$68.95M$455,000.00-0.3030Analyst Forecast
Positive News
Gap Up
PVLA
Palvella Therapeutics
3.6245 of 5 stars
$21.72
-1.6%
$44.43
+104.6%
N/A$239.85M$42.81M-1.80N/AEarnings Report
ATXS
Astria Therapeutics
2.2981 of 5 stars
$4.25
-3.8%
$30.00
+605.9%
-58.2%$239.84MN/A-2.0330Earnings Report
Analyst Forecast
SLRN
Acelyrin
2.7506 of 5 stars
$2.37
-2.1%
$9.60
+305.1%
-56.7%$239.15MN/A-0.96135Earnings Report
Positive News
ITOS
iTeos Therapeutics
2.8287 of 5 stars
$6.24
-3.1%
$25.50
+308.7%
-54.5%$238.83M$35M-1.9890Analyst Downgrade
News Coverage
CMPX
Compass Therapeutics
3.7967 of 5 stars
$1.73
-2.0%
$13.38
+675.4%
+23.8%$238.54M$850,000.00-4.6620Earnings Report
Analyst Revision
ALMS
Alumis
2.61 of 5 stars
$5.01
+4.6%
$25.86
+416.1%
N/A$236.58MN/A0.00N/AEarnings Report
Positive News
Gap Up
MNPR
Monopar Therapeutics
2.9567 of 5 stars
$38.67
-0.3%
$55.33
+43.1%
+1,040.1%$236.47MN/A-19.6310Earnings Report
Gap Down
GLUE
Monte Rosa Therapeutics
2.1873 of 5 stars
$3.83
-0.5%
$15.50
+304.7%
-26.0%$235.58M$75.62M-2.0990Earnings Report
Analyst Revision
News Coverage
CDTX
Cidara Therapeutics
4.4389 of 5 stars
$18.77
-1.1%
$39.14
+108.5%
+47.5%$235.51M$1.28M-0.7490Earnings Report
AARD
Aardvark Therapeutics
N/A$10.68
+0.5%
$31.50
+194.9%
N/A$231.71MN/A0.0018Earnings Report
News Coverage
Gap Up
Trading Halted

Related Companies and Tools


This page (NASDAQ:APLT) was last updated on 5/15/2025 by MarketBeat.com Staff
From Our Partners